NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

5881. Human immunodeficiency virus-1 infection: developing systemic drug products for pre-exposure prophylaxis

5882. Interpretation of and compliance policy for certain label requirement: applicability of certain Federal Food, Drug, and Cosmetic Act requirements to vape shops

5883. Standards development and the use of standards in regulatory submissions reviewed in the Center for Biologics Evaluation and Research

5884. Pediatric information incorporated into human prescription drug and biological product labeling

5885. Recommended content and format of non-clinical bench performance testing information in premarket submissions: guidance for industry and Food and Drug Administration staff

5886. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

5887. REMS: FDA's application of statutory factors in determining when a REMS is necessary

5888. Extending expiration dates of doxycycline tablets and capsules in strategic stockpiles: guidance for government public health and emergency response stakeholders

5889. Class II special controls guideline: in vitro diagnostic devices for Bacillus spp. detection : guideline for industry and Food and Drug Administration staff

5890. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff